Senores Pharmaceuticals Limited — PPTs, 27-07-2026: Investor Presentation

Senores Pharma delivered robust Q1 FY27 performance. Revenue surged 36% YoY to ₹180.2 Cr, primarily driven by strong growth in Regulated Markets (+42% YoY to ₹127.8 Cr) and Emerging Markets (+30% YoY to ₹37.6 Cr). EBITDA jumped 87% YoY to ₹53.8 Cr, with margins expanding by 810 bps to 29.8%. Profit after Tax (PAT) grew 56% to ₹30.7 Cr.

The company’s growth strategy focuses on launching high-potential products in the US, expanding into B2C and government sales, and enhancing market presence in regulated markets. Recent developments include a US joint venture, Amerisyn LLC, for federal supplies, and acquiring a 75% stake in Apnar Pharmaceuticals. Management indicates strong growth visibility from a robust pipeline, targeting over $740 million in gross market share from 136 upcoming ANDA products.